KALA BIO Halts Eye Drug Development After Trial Failure
KALA BIO’s lead drug, KPI-012, failed its Phase 2b trial for Persistent Corneal Epithelial Defect (PCED), prompting the company to stop development and pursue cash-saving strategic options.
/ 935 items
#Healthcare↓
Larimar Stock Plummets: Anaphylaxis Events in Drug Study
Larimar's experimental drug for Friedreich's ataxia, nomlabofusp, showed positive biological results and improved clinical trends, but safety concerns over seven cases of anaphylaxis caused the stock to drop dramatically.
IO Biotech Restructuring After Cylembio BLA Rejection
IO Biotech won't submit its Cylembio cancer vaccine application after the FDA recommended against it due to trial results narrowly missing significance. IOBT will plan a new study and cut 50% of staff to save cash.
Enanta Stock Drops After Mixed Results from RSV Drug Trial
Enanta Pharmaceuticals' experimental RSV drug caused stock market disappointment after failing its main goal (reducing symptom time). However, the trial showed success in important secondary areas, like clearing the virus faster.
FDA Greenlights RAPT's Next-Gen Food Allergy Treatment Trial
FDA OKs major trial (prestIgE) for RPT904, a next-gen anti-IgE drug. It will treat ~100 people allergic to peanut, milk, or egg. The goal is a better, safe therapeutic option by blocking IgE, the key driver of these allergies.
Genmab's $8 Billion Move: Acquiring Merus to Lead the Next Wave of Cancer Antibody Therapeutics
Denmark's Genmab is acquiring Dutch drugmaker Merus for $8 billion to secure petosemtamab, a late-stage, breakthrough treatment for head and neck cancer, bolstering Genmab's proprietary oncology pipeline and accelerating its evolution into a global biotechnology leader.